SLD

Immuneering Reports First Quarter 2024 Financial Results and Provides Business Updates

Retrieved on: 
Tuesday, May 7, 2024
Neoplasm, FDA, Cancer, Research and development, Fast Track, Fast track (FDA), SLD, Safety, Food, Pancreatic cancer, Research, RECIST, Synergy, RAS, Half-life, Administration, Cycle, PDAC, Human, Pancreas, Patient, MAPK, Acquisition, AACR, RAF, DCI, PD, Annual general meeting, G&A, Growth, Amgen, Pharmaceutical industry

CAMBRIDGE, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, today reported financial results for the first quarter ended March 31, 2024, and provided business updates.

Key Points: 
  • As reported at the data cutoff date of February 20, 2024, IMM-1-104 was observed to be well-tolerated, demonstrating the potential for a differentiated safety profile.
  • Initial data from multiple arms of the Phase 2a portion of the Company’s Phase 1/2a study expected in 2024.
  • Research and Development (R&D) Expenses: R&D expenses for the first quarter of 2024 were $11.2 million compared with $10.2 million for the first quarter of 2023.
  • General and Administrative (G&A) Expenses: G&A expenses for the first quarter of 2024 were $4.1 million compared with $4.5 million for the same period of 2023.

Immuneering Announces Positive Topline Results from Phase 1 Portion of its Phase 1/2a Clinical Trial of IMM-1-104 in RAS-Mutant Solid Tumors

Retrieved on: 
Thursday, March 14, 2024
Toxicity, Concept, Plasma, Candidate, RECIST, Oncology, RAS, Patient, FACP, City, Cancer, Pancreatic cancer, Neoplasm, Therapy, Safety, Pharmacokinetics, SLD, Pharmaceutical industry

“Today’s results are an important step towards that goal, as we share positive topline data from the Phase 1 portion of our Phase 1/2a clinical trial of IMM-1-104 in advanced RAS-mutant solid tumors.

Key Points: 
  • “Today’s results are an important step towards that goal, as we share positive topline data from the Phase 1 portion of our Phase 1/2a clinical trial of IMM-1-104 in advanced RAS-mutant solid tumors.
  • Immuneering evaluated both 240mg and 320mg QD as prospective doses for the Phase 2a portion of its Phase 1/2a study.
  • The Phase 2a portion is expected to include up to twenty clinical sites and has already dosed its first patient.
  • Initial data from multiple arms of the Phase 2a portion of Immuneering’s Phase 1/2a study of IMM-1-104 expected in 2024.

Sigma Debuts 15mm F1.4 Ultra-Wide, 500mm F5.6 Super-Tele Prime Lenses - YouTube Introduction Information at B&H

Retrieved on: 
Wednesday, February 21, 2024
Light, Sony, HLA, B&H, Lens, Art, Sport, Element, FLD, SLD, Reproduction, Motion, Environment, Camera

NEW YORK, Feb. 20, 2024 /PRNewswire/ -- B&H is pleased to announce new prime lenses from Sigma's Art and Sports lines for mirrorless cameras: the 15mm f/1.4 DG DN Art and the 500mm f/5.6 DG DN OS Sports lenses. Available in L-mount and Sony E-mount configurations, the pair offers exceptional imaging and professional-grade performance at both ends of the focal-length spectrum.

Key Points: 
  • Sigma expands its Art and Sports lines for mirrorless with a 15mm f/1.4 diagonal fisheye and the handheld-friendly, super-telephoto 500mm f/5.6 lens.
  • NEW YORK, Feb. 20, 2024 /PRNewswire/ -- B&H is pleased to announce new prime lenses from Sigma's Art and Sports lines for mirrorless cameras : the 15mm f/1.4 DG DN Art and the 500mm f/5.6 DG DN OS Sports lenses.
  • Take a night walk on the wide side with Sigma's latest astro-centric offering, the 15mm f/1.4 DG DN Art lens.
  • Joining two 14mm lenses and a 20mm lens, this bright, ultra-wide prime distinguishes itself as the line's only diagonal fisheye.

Give the Ultimate Valentine’s Day Gift with Tickets to the Stags Leap District Winegrowers Vineyard to Vintner Weekend, Held April 26 – 28, 2024

Retrieved on: 
Wednesday, February 7, 2024
Collaboration, Deer, Taste, Vineyard, History, Baldacci Family Vineyards, Cabernet Sauvignon, Love, Rhythm, Intimate, Art, SLD, Sale, Degustation, Wine, Leap year

Napa’s neighborhood for world-class Cabernet, the tiny Stags Leap District is renowned for producing wines with recognizable grace and power.

Key Points: 
  • Napa’s neighborhood for world-class Cabernet, the tiny Stags Leap District is renowned for producing wines with recognizable grace and power.
  • The event also features a “first sip” of the extremely limited 2022 Stags Leap District Cabernet Sauvignon: A Collaboration.
  • The 2024 Vineyard to Vintner highlights include:
    Friday, April 26 – Vintner-hosted Library Wine Dinners – Elegant, intimate gatherings feature rare and library selections.
  • The wine will be released in Fall 2024 and available for sale exclusively through the Stags Leap District Winegrowers website between October 15 and December 14, 2024.

WPS Announces Revolutionary Dyslexia Assessment and Intervention

Retrieved on: 
Wednesday, January 31, 2024
Multimedia, Growth, Head, Spectrum, Occupational therapy, SLD, Risk, Acquisition, Learning, WPS, Nursing

This groundbreaking assessment represents a pivotal moment in dyslexia evaluation, promising unparalleled efficiency, and effectiveness in connecting assessment with targeted interventions.

Key Points: 
  • This groundbreaking assessment represents a pivotal moment in dyslexia evaluation, promising unparalleled efficiency, and effectiveness in connecting assessment with targeted interventions.
  • The Tests of Dyslexia (TOD™) emerges as a beacon of innovation, addressing these challenges head-on and presenting an all-encompassing solution to dyslexia assessment and intervention.
  • The TOD™ stands out as the first comprehensive assessment tool to seamlessly integrate dyslexia assessment with interventions tailored to individual needs.
  • The company's steadfast commitment to excellence and innovation continues with the introduction of the Tests of Dyslexia (TOD™), positioning WPS at the forefront of progress in dyslexia assessment and intervention.

Riverside Insights and CAI Founders to Host Virtual Conference on SLD Identification

Retrieved on: 
Tuesday, November 28, 2023
CAI, Genetics, NASP, Continuing education, Cognitive neuroscience, WJ, Neuropsychology, Mathematics, APA, Single Supervisory Mechanism, Intervention, Unified, Better, Learning, National Association, Report, Practice, Conference, Riverside Insights, American Psychological Association, SLD, Conjugated estrogens, Art, Nursing, Tutoring, Education, Research, Intelligence

ITASCA, Ill., Nov. 28, 2023 /PRNewswire-PRWeb/ -- Riverside Insights®, a leading developer of research-based assessments and analytics, today announced it is teaming up with Dr. Dawn P. Flanagan, Dr. Vincent C. Alfonso and Dr. Samuel O. Ortiz, creators of the Cross-Battery Assessment Approach and founders of Comprehensive Assessment for Intervention (CAI), to host their first annual virtual conference featuring researchers, scholars, and educators dedicated to advancing the field of specific learning disabilities (SLD) identification and intervention. The CAI Conference - State of the Art of SLD Identification: Innovations in Theory, Research, and Practice - will take place January 25-26, 2024, and enable participants to earn continuing education (CE) credit.

Key Points: 
  • Dawn P. Flanagan, Dr. Vincent C. Alfonso and Dr. Samuel O. Ortiz, creators of the Cross-Battery Assessment Approach and founders of Comprehensive Assessment for Intervention (CAI), to host their first annual virtual conference featuring researchers, scholars, and educators dedicated to advancing the field of specific learning disabilities (SLD) identification and intervention.
  • The CAI Conference - State of the Art of SLD Identification: Innovations in Theory, Research, and Practice - will take place January 25-26, 2024, and enable participants to earn continuing education (CE) credit.
  • CAI 2024 brings together a premier line-up of world-renowned presenters including researchers, scholars, and educators dedicated to advancing the field of SLD identification and intervention.
  • "CAI 2024 brings together a premier line-up of world-renowned presenters including researchers, scholars, and educators dedicated to advancing the field of SLD identification and intervention," said Dr. Sarah Holman, director, Riverside Insights.

Can-Fite Issues Business Update: All Clinical Programs and Business Development Activities Remain Solidly on Track

Retrieved on: 
Wednesday, November 1, 2023
Biotechnology, Pharmaceutical, Finance, Oncology, General Health, Health, Professional Services, Clinical Trials, Oculocerebrorenal syndrome, Psoriasis, NYSE, Food, Inflammation, European Medicines Agency, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Artificial intelligence, Liver cancer, CANF, NASH, Partnership, Machine learning, Pancreatic cancer, Consultant, TASE, A3, SLD, Pharmaceutical industry

(NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today confirmed that all of the Company’s clinical and business development activities are ongoing and proceeding by both its Israeli and US based staff.

Key Points: 
  • (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today confirmed that all of the Company’s clinical and business development activities are ongoing and proceeding by both its Israeli and US based staff.
  • “Can-Fite remains focused and stronger than ever in our purpose to bring medications to market that improve and save lives.
  • All the investigators participating in the conductance of the clinical studies are working full force and continue patient enrolment for the ongoing advanced clinical studies,” stated Dr. Pnina Fishman, Can-Fite’s Chief Scientific Officer and Executive Chairman.
  • Phase II trials include an ongoing study for steatotic liver disease (SLD), formerly known as NASH, and preparatory work is underway for a Phase IIa trial in pancreatic cancer.

National Liver Health Awareness Month Highlights the Urgent Need for Liver Disease Prevention

Retrieved on: 
Wednesday, October 4, 2023
Steatosis, Fatty liver disease, NASH, Education, Hepatology, Liver disease, Liver cancer, Cirrhosis, MASH, Transaminase, Houston Methodist Hospital, Metabolism, Hepatitis, Name, Patient, Physician, NAFLD, SLD, Dietary supplement

PARIS, Oct. 4, 2023 /PRNewswire/ -- As we approach October's National Liver Health Awareness Month, Echosens, a manufacturer of non-invasive diagnostic technology, FibroScan®, is urgently calling attention to the importance of prioritizing liver health. The company underscores the significant role of regular liver screenings, particularly non-invasive ones, in detecting and preventing various liver diseases, such as Hepatitis, Fatty Liver Disease, Cirrhosis, and Liver Cancer. Echosens points out that public awareness and information about these diseases are currently insufficient, emphasizing the need for more education and awareness.

Key Points: 
  • The company underscores the significant role of regular liver screenings, particularly non-invasive ones, in detecting and preventing various liver diseases, such as Hepatitis, Fatty Liver Disease, Cirrhosis, and Liver Cancer.
  • This year's focus is increasing awareness of liver disease and highlighting the recent changes in terminology for fatty liver disease, now referred to as steatotic liver disease (SLD).
  • The terms nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) have been superseded by metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH), respectively.
  • For more information about liver health, liver disease, and Echosens' initiatives, please visit www.echosens.com .

Schneider Electric Demonstrates Industry-Leading Energy Management Solutions at NECA 2023

Retrieved on: 
Friday, September 29, 2023
NECA, EV, Software, IBM Power Systems, QR, Automation, Erongo Battery Energy Storage System, Schneider Electric, System, SLD, NFPA, Safety, BESS, Television

PHILADELPHIA, Sept. 29, 2023 /PRNewswire/ -- Schneider Electric , the leader in the digital transformation of energy management and automation, today announced a broad portfolio of product innovations at the NECA 2023 Convention & Trade Show taking place September 29 through October 2 in Philadelphia, PA.

Key Points: 
  • PHILADELPHIA, Sept. 29, 2023 /PRNewswire/ -- Schneider Electric , the leader in the digital transformation of energy management and automation, today announced a broad portfolio of product innovations at the NECA 2023 Convention & Trade Show taking place September 29 through October 2 in Philadelphia, PA.
  • Schneider Home , a first-of-its-kind integrated home energy management solution that makes homes more efficient and resilient, will be premiered to industry professionals at the event.
  • Schneider Home provides energy independence for homeowners – automating energy production, storage, measurement, and control – all from a single, easy-to-use app.
  • In contrast to existing solutions, requiring separate apps and disjointed hardware, Schneider Home eliminates that complexity, allowing homeowners to easily manage energy usage and reduce costs.

Web3 TLDs and Domains Platform Freename Raises $2.5 Million in Seed Round

Retrieved on: 
Wednesday, September 6, 2023
Web 2.0, Internet, Growth, SLD, Top-level domain, Cryptocurrency

This round will fuel Freename growth and accelerate the development of its platforms

Key Points: 
  • This round will fuel Freename growth and accelerate the development of its platforms
    Since 2022, the company has been providing top level domains (TLDs) and second level domains (SLDs) on multiple blockchains.
  • Web3 domains represent a digital identity and can be used for various functions such as sending and receiving crypto payments, sending web2 and web3 emails, browsing traditional websites as well as building decentralized ones.
  • Davide, CEO and co-founder of Freename, emphasizes that, "Freename's goal is to redefine the Web3 Domain Naming System.
  • Our team and community are growing, driven by the passion to change the market by making Web3 domains increasingly user-friendly and compatible with the traditional Internet.